|
|
 Library
of Slides and Posters |
|
|
Analysis
of clinical outcomes in African American HIV-1 positive patients receiving
lopinavir/ritonavir in a large
urban AIDS clinic
P Kadlecik and others. AIDS 2010. |
|
|
Limited
future regimen options for those starting
on NNRTI-based triple combinations due to antiretroviral
drug resistance mutations
K Chan and others. AIDS 2010. |
|
|
Clinical
outcomes, immmunologic function and virologic suppression among HIV
infected children receiving Lopinavir/ritonavir-based
second line antiretroviral therapy at National Pediatric
Hospital, Phnom Penh, Cambodia
S Sophan and others. AIDS 2010. |
|
|
Comparison
of total and unbound lopinavir (LPV)
pharmacokinetics (PK) in HIV-infected pregnant women receiving lopinavir/ritonavir
(LPV/r) soft-gel capsules (SGC) or tablets
G Taylor and others. AIDS 2010. |
|
|
Single
boosted protease inhibitor versus double boosted protease inhibitors
for the salvage therapy in HIV-infected patients
W Manosuthi and others. AIDS 2010. |
|
|
Antiretroviral
monotherapy with ritonavir-boosted lopinavir
or fosamprenavir in HIV-cirrhotic patients is a safe, effective
and costs-saving strategy
A Moreno-Zamora and others. AIDS 2010. |
|
|
Lopinavir/ritonavir
combined with raltegravir demonstrated similar antiviral
efficacy and safety as lopinavir/ritonavir
combined with tenofovir disoproxil fumarate/emtricitabine
in treatment-naïve HIV-1 infected subjects
J Reynes and others. AIDS 2010. |
|
|
Baseline
HIV-1 RNA does not affect virologic response to lopinavir/ritonavir-based
regimens in antiretroviral-naive subjects: results of a
96-week meta-analysis of >2400 subjects
J van Wyk and others. AIDS 2010 |
|
|
Market
shift towards heat-stable lopinavir/ritonavir
demonstrates the need for improved formulations for second
line treatment of HIV/AIDS in low- and middle-income countries
B Waning and others. AIDS 2010. |
|
|
The
effect of lopinavir/r monotherapy
on viral load and on the selection of resistance-associated mutations
in seminal plasma
E Nunes and others. AIDS 2010. |
|
|
Incidence
of emtricitabine, tenofovir, raltegravir,
and lopinavir resistance following twice-daily (BID) lopinavir/ritonavir
(LPV/r) in combination with once-daily (QD) emtricitabine/tenofovir
(FTC/TDF) or twice daily raltegravir
(RAL) in antiretroviral-naïve, HIV-1 infected subjects:
48-week results of a 96-week randomized trial (study M10-336)
A Lawal and others. AIDS 2010. |
|
|
The
effect of lopinavir/ritonavir
on the pharmacokinetics of TMC207, an investigational antimycobacterial
agent
R van Heeswijk and others. AIDS 2010. |
|
|
Real-life
safety and efficacy of lopinavir/ritonavir
(LPV/r) in drug-naive and antiretroviral (ARV) treatment-experienced
HIV patients: 96-week follow-up
B Conway and others. AIDS 2010 |
|
|
Drug-resistant
genotyping to guide selection of etravirine,
darunavir and raltegravir in salvage therapy for multi-drug-resistant
cases improves outcomes
N Miyazaki and others. AIDS 2010. |
|
|
Duration
of antiretroviral regimens including Raltegravir,
Maraviroc, Darunavir and/or Etravirine in clinical practice
I Castillo and others. AIDS 2010. |
|
|
Raltegravir
and enfuvirtide as a "bridge" antiretroviral
therapy in kidney-transplanted patients with HIV infection receiving
everolimus and low-dose cyclosporine: a case-control study
S Cocchi and others. AIDS 2010. |
|
|
Impact
of raltegravir on immune reconstitution
and thymopoiesis in HIV-1-infected patients with undetectable viremia
on HAART
C Garrido and others. AIDS 2010. |
|
|
Impact
of the HIV-1 integrase flexibility on the alternative resistance pathways
to raltegravir
S Abdel-Azeim and others. AIDS 2010. |
|
|
Immunological
benefit of raltegravir when used
as part of switch strategies
C Garrido and others. AIDS 2010. |
|
|
Early
viral response in a cohort of heavily ARV-experienced patients receiving
a salvage regimen recommended
by a national advisory board in Mexico
Y Vargas-Infante and others. AIDS 2010. |
|
|
Raltegravir-based-HAART
and lymphoma chemotherapy
S Marcotte and others. AIDS 2010. |
|
|
Virological
response to atazanavir, ritonavir and tenofovir/emtricitabine:
relation to individual pharmacokinetic parameters and adherence measured
by medication events monitoring system (MEMS) in naïve HIV-infected
patients (ANRS134 trial)
C Goujard and others. AIDS 2010. |
|
|
METABOLIK
(Metabolic Evaluation in Treatment-naïves Assessing the impact
of two BOosted protease inhibitors on LIpids and other marKers): comparison
of the metabolic effects of darunavir/ritonavir
versus atazanavir/ritonavir over 12 weeks
J Aberg and others. AIDS 2010. |
|
|
Long-term
efficacy and safety of a switch to unboosted atazanavir
(ATV) in well controlled HIV-1 infected patients, results
of the NEAT Unboosted Atazanavir Cohort
A Rachline and others. AIDS 2010. |
|
|
Safety
and efficacy of treatment simplification to atazanavir/ritonavir
plus lamivudine in patients on two NRTIs plus atazanavir/ritonavir
with optimal virologic control: 24 weeks results from a pilot study
(atazanavir and lamivudine simplification study, ATLAS)
A De Luca and others. AIDS 2010. |
|
|
Risk
of Neutropenia, anemia and skin-rash among HIV exposed infants receiving
nevirapine and cotrimoxazole
compared to cotrimoxazole prophylaxis alone
J Aizire and others. AIDS 2010. |
|
|
Randomized
trial comparing two nevirapine
starting doses after switching from efavirenz
due to side effects (the Venice/GESIDA-4905 study)
E Ribera and others. AIDS 2010. |
|
|
Influence
of CYP2B6 haplotype on plasma
efavirenz and nevirapine levels when co-administered with rifampicin
in HIV/TB co-infected Thai adults
S Uttayamakul and others. AIDS 2010. |
|
|
Treatment
outcomes of patients co-infected with HIV
and tuberculosis who received nevirapine-based
antiretroviral regimen: a 4-year prospective study
W Manosuthi and others. AIDS 2010 |
|
|
Comparison
of 48 week efficacy and safety of 400 mg QD nevirapine extended release
formulation (Viramune XR) versus
200 mg BID nevirapine immediate release formulation (Viramune
IR) in combination with Truvada
in antiretroviral (ARV) naïve HIV-1 infected patients (VERxVE)
J Gathe and others. AIDS 2010 |
|
|
Both
Immune Activation and Viral Load are Reduced Within 28 Days by VS411,
the First AntiViral-HyperActivation Limiting Therapeutic (AV-HALT).
A Phase II Study
E Katabira and others. AIDS 2010. |
|
|
DermaVir
for initial treatment of HIV-infected subjects demonstrates preliminary
safety, immunogenicity and HIV-RNA reduction versus placebo immunization
J Lunzen and others. AIDS 2010. |
|
|
Pooled
Week 48 efficacy and safety results from ECHO and THRIVE, two double-blind,
randomised, Phase III trials comparing TMC278
versus efavirenz in treatment-naïve, HIV-1-infected patients
C Cohen and others. AIDS 2010. |
|
|
Pharmacokinetic
interaction study between TMC278,
a next-generation NNRTI, and methadone
H Crauwels and others. AIDS 2010. |
|
|
Relative
bioavailability of a concept paediatric formulation of TMC278,
an investigational NNRTI
H Crauwels and others. AIDS 2010. |
|
|
Darunavir/ritonavir
increases rosuvastatin concentrations but does not alter lipid lowering
effect in healthy volunteers
C Fichtenbaum and others. AIDS 2010. |
|
|
Hepatic
laboratory parameters in the MONET Trial: association with Hepatitis
C co-infection
M Nelson and others. AIDS 2010. |
|
|
The
MONET trial 96 week analysis: darunavir/r
monotherapy versus darunavir/r + 2NRTIs, for patients with
HIV RNA < 50 copies/mL at baseline
A Rieger and others. AIDS 2010. |
|
|
Effect
of adherence on virological response to once-daily versus twice-daily
darunavir/ritonavir in treatment-experienced,
HIV-1-infected patients with no darunavir resistance-associated mutations:
ODIN 48-week data
C Workman and others. AIDS 2010. |
|
|
Effects
of once-daily versus twice-daily darunavir/ritonavir
on lipid parameters at Week 48 in treatment-experienced, HIV-1-infected
patients with no darunavir resistance-associated mutations in the
ODIN study
J Arribas and others. AIDS 2010. |
|
|
Subgroup
analysis and predictors of virological response in treatment-experienced,
HIV-1-infected patients in the ODIN trial
P Cahn and others. AIDS 2010. |
|
|
METABOLIK
(Metabolic Evaluation in Treatment-naïves Assessing the impact
of two Boosted protease inhibitors on LIpids and other marKers): Comparison
of the Metabolic Effects of Darunavir/ritonavir
versus Atazanavir/ritonavir over 12Weeks
J Aberg and others. AIDS 2010. |
|
|
The
SENSE Trial: Etravirine (ETR)
shows fewer Neuropsychiatric Adverse Events than Efavirenz
(EFV) in Treatment-naïve HIV-1 Infected Patients
B Gazzard and others. AIDS 2010. |
|
|
Prevalence
of genotypic and phenotypic susceptibility to etravirine
in US samples received for routine resistance testing
G Picchio and others. AIDS 2010. |
|
|
SWITCH-EE
Study: A Randomized Cross-over Study to Compare Etravirine
and Efavirenz treatment
A Nguyen and others. AIDS 2010. |
|
|
Bioequivalence
of the Co-Formulation of Emtricitabine/Rilpivirine/Tenofovir
DF
A Mathias and others. AIDS 2010. |
|
|
Switching
from Kivexa [ABC/3TC ]+Kaletra [LPV/r] to Truvada
[TDF/FTC]+Kaletra [LPV/r] Reduces High Cholesterol: Results of a 12
Week Randomized, Controlled Study (ROCKET II)
G Behrens and others. AIDS 2010. |
|
|
Switching
to Atripla® (EFV/FTC/TDF)
from ABC/3TC FDC (Kivexa®/Epzicom®)
+ Efavirenz (EFV) Improves Lipid
Levels Towards NCEP Recommendations: Primary Endpoint Results of a
24-week Randomised Study
G Moyle and others. AIDS 2010. |
|
|
The
SPARTAN Study: A Pilot Study to Assess the Safety and Efficacy of
an Investigational NRTI- and RTV-Sparing
Regimen of Atazanavir
(ATV) Experimental Dose of 300mg BID plus Raltegravir
(RAL) 400mg BID (ATV+RAL) in Treatment-Naïve HIV-Infected Subjects.
M Kozal and others. AIDS 2010. |
